I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy

Recruiting Observational Study
Non Small Cell Lung Cancer Lung Cancer Metastatic Lung Cancer, Nonsmall Cell Lung Adenocarcinoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
2,200 (estimated)
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
I3LUNG is an international project aiming to develop a medical device to predict immunotherapy efficacy for NSCLC patients using the integration of multisource data (real word and multi-omics data). This objective will be reached through a retrospective - setting up a transnational platform of available data from 2000 patients - and a prospective - multi-omics prospective data collection in 200 NS…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age \>/= 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status \</= 2. * Histologically confirmed diagnosis of stage IIIB/C-IV Non-Small-Cell Lung Cancer * Received any line immunotherapy (maintenance therapy with Durvalumab is allowed) for retrospective coh…
Contacts

Arsela Prelaj, MD

+39 022390 3647

arsela.prelaj@istitutotumori.mi.it

CONTACT